147 related articles for article (PubMed ID: 17713466)
1. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
Ntukidem NI; Nguyen AT; Stearns V; Rehman M; Schott A; Skaar T; Jin Y; Blanche P; Li L; Lemler S; Hayden J; Krauss RM; Desta Z; Flockhart DA; Hayes DF;
Clin Pharmacol Ther; 2008 May; 83(5):702-10. PubMed ID: 17713466
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results.
Hayes DF; Skaar TC; Rae JM; Henry NL; Nguyen AT; Stearns V; Li L; Philips S; Desta Z; Flockhart DA;
Clin Pharmacol Ther; 2010 Nov; 88(5):626-9. PubMed ID: 20827267
[TBL] [Abstract][Full Text] [Related]
3. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
Henry NL; Nguyen A; Azzouz F; Li L; Robarge J; Philips S; Cao D; Skaar TC; Rae JM; Storniolo AM; Flockhart DA; Hayes DF; Stearns V
Br J Cancer; 2010 Jan; 102(2):294-300. PubMed ID: 19953095
[TBL] [Abstract][Full Text] [Related]
5. The association of bone mineral density with estrogen receptor gene polymorphisms.
Greendale GA; Chu J; Ferrell R; Randolph JF; Johnston JM; Sowers MR
Am J Med; 2006 Sep; 119(9 Suppl 1):S79-86. PubMed ID: 16949392
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen therapy in breast cancer: do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?
Gaibar M; Fernández G; Romero-Lorca A; Novillo A; Tejerina A; Bandrés F; Fernández-Santander A
Int J Biol Markers; 2013 Dec; 28(4):e371-6. PubMed ID: 23828408
[TBL] [Abstract][Full Text] [Related]
7. Association of PvuII and XbaI polymorphisms on estrogen receptor alpha (ESR1) gene to changes into serum lipid profile of post-menopausal women: Effects of aging, body mass index and breast cancer incidence.
Gomes-Rochette NF; Souza LS; Tommasi BO; Pedrosa DF; Eis SR; Fin ID; Vieira FL; Graceli JB; Rangel LB; Silva IV
PLoS One; 2017; 12(2):e0169266. PubMed ID: 28199328
[TBL] [Abstract][Full Text] [Related]
8. Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women's Health Across the Nation (SWAN).
Sowers MR; Symons JP; Jannausch ML; Chu J; Kardia SR
Am J Med; 2006 Sep; 119(9 Suppl 1):S61-8. PubMed ID: 16949390
[TBL] [Abstract][Full Text] [Related]
9. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
Ilanchezhian S; Thangaraju M; Sachdanandam P
Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
[TBL] [Abstract][Full Text] [Related]
10. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women.
Rivadeneira F; van Meurs JB; Kant J; Zillikens MC; Stolk L; Beck TJ; Arp P; Schuit SC; Hofman A; Houwing-Duistermaat JJ; van Duijn CM; van Leeuwen JP; Pols HA; Uitterlinden AG
J Bone Miner Res; 2006 Sep; 21(9):1443-56. PubMed ID: 16939403
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
[TBL] [Abstract][Full Text] [Related]
13. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
14. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.
Almeida S; Fiegenbaum M; de Andrade FM; Osório-Wender MC; Hutz MH
Maturitas; 2006 May; 54(2):119-26. PubMed ID: 16242874
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Onitilo AA; McCarty CA; Wilke RA; Glurich I; Engel JM; Flockhart DA; Nguyen A; Li L; Mi D; Skaar TC; Jin Y
Breast Cancer Res Treat; 2009 Jun; 115(3):643-50. PubMed ID: 19082882
[TBL] [Abstract][Full Text] [Related]
16. Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis.
Morón FJ; Mendoza N; Vázquez F; Molero E; Quereda F; Salinas A; Fontes J; Martínez-Astorquiza T; Sánchez-Borrego R; Ruiz A
Bone; 2006 Jul; 39(1):213-21. PubMed ID: 16530497
[TBL] [Abstract][Full Text] [Related]
17. Associations of estrogen receptor alpha and Beta gene polymorphisms with lipid levels and insulin resistance in men.
Efstathiadou ZA; Sakka C; Polyzos SA; Goutou M; Stakias N; Bargiota A; Koukoulis GN
Metabolism; 2015 May; 64(5):611-7. PubMed ID: 25665486
[TBL] [Abstract][Full Text] [Related]
18. Exonic, but not intronic polymorphisms of ESR1 gene might influence the hypolipemic effect of raloxifene.
Zavratnik A; Prezelj J; Kocijancic A; Marc J
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):22-6. PubMed ID: 17350824
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
20. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
